Nama's AI scorecard currently rates Kymera Therapeutics Sell (1.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does KYMR report earnings?

Kymera Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$1.26.

What is the KYMR price target?

The median analyst price target from 23 analysts is $144.00, with a range of $116.00 – $180.00.

Is KYMR Shariah compliant?

Nama's AAOIFI-style screen reads Kymera Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Kymera Therapeutics (KYMR)

Healthcare · Biotechnology · NASDAQ

Kymera Therapeutics (KYMR) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $11.25B and a free-cash-flow yield of -2.1%. Over the most recent reported fiscal year, revenue declined 16.7%. Nama's AI scorecard rates it Sell, 1.8 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 1.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +77.6% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-4.5%

How far the last close sits under the highest price of the past five years.

Market cap	$11.25B
Trailing P/E	—
Price / book	7.0
Price / sales	109.8
FCF yield	-2.1%
Dividend yield	—
Gross margin	0.0%
Operating margin	-396.0%
Net margin	0.0%
Revenue growth (YoY)	-16.7%
Revenue growth (3-yr annual)	-5.7%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

KYMR earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$1.26). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	-$1.32	-$1.27	-3.9%	$0
Q2 2026	Aug 5, 2026	-$0.62	-$0.74	+16.2%	$65.00M
Q1 2026	Apr 30, 2026	-$0.71	-$0.86	+17.4%	$34.37M
Q4 2025	Feb 26, 2026	-$0.98	-$0.77	-27.3%	$2.87M

KYMR analyst price target

Median target $144.00 from 23 analysts, ranging $116.00 – $180.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live KYMR data on Nama Insights →

KYMR FAQ

Is KYMR a buy?: Nama's AI scorecard currently rates Kymera Therapeutics Sell (1.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does KYMR report earnings?: Kymera Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$1.26.
What is the KYMR price target?: The median analyst price target from 23 analysts is $144.00, with a range of $116.00 – $180.00.
Is KYMR Shariah compliant?: Nama's AAOIFI-style screen reads Kymera Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.